Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinblastine + sirolimus
- Development stage
- Unknown
- Lead developer
- SickKids
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of vinblastine, a vinca alkaloid that inhibits mitosis by binding to tubulin, and sirolimus (rapamycin), an mTOR inhibitor. This combination has been studied primarily for pediatric patients with recurrent or refractory solid tumors, including neuroblastoma and CNS tumors. The combination works through both anti-proliferative and anti-angiogenic mechanisms, showing synergistic effects in inhibiting tumor growth, inducing apoptosis, and reducing angiogenesis.
02
Targets
Mechanistic target of rapamycin complex 1TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vinblastine + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinblastine + sirolimus.